Meanwhile, a recent preclinical study of taVNS treatment in rats with post-stroke dysphagia found that it significantly increased the number of swallowing times within 20 s, the expression of vascular endothelial growth factor, and basic fibroblast growth factor. This evidence concerns the gene FGF2 and stroke disorder.